Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...

Durvalumab is currently approved for a number of cancer types. Though not approved in gastric cancer, the MATTERHORN regimen ...

Feeling sick at sea? Learn what to do right away, from alerting the ship's doctor to managing your symptoms and preventing an ...

Regulatory burdens have raised the capital requirements for early-stage companies, causing many to do what would have been ...

Determining the diversity and distribution of species in an ecosystem is essential to creating a baseline for monitoring ...

Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting ...

The emergence of advanced therapy medicinal products (ATMPs) including cell therapies, has led to many bioanalytical ...

CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today presented compelling primary results from the Phase 2 GDFATHER-NEO trial in an oral late-breaking session at the European ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark ...

Dianna Gunn built her first WordPress website in 2008. Since then, she's poured thousands of hours into understanding how websites and online businesses work. She's shared what she's learned on blogs ...

In their years in the force, these women investigators have proved their mettle — whether it is questioning suspects, ...